What it's for (Indications)
- Iron polymaltose is indicated for the treatment and prophylaxis of iron deficiency across various patient populations.
- This includes individuals diagnosed with iron deficiency anemia (IDA) based on laboratory parameters such as low serum ferritin levels, reduced hemoglobin and hematocrit, and microcytic, hypochromic red blood cell morphology.
- It is also utilized for latent iron deficiency, where iron stores are depleted but anemia has not yet manifested.
- Prophylactic iron supplementation is frequently recommended during periods of increased iron demand, notably throughout pregnancy and lactation, in rapidly growing adolescents, and in individuals undergoing dialysis.
- Furthermore, it may be prescribed for patients with inadequate dietary iron intake, malabsorption syndromes, or chronic blood loss, where dietary measures alone are insufficient to restore iron balance.
- The goal of treatment is to replenish systemic iron stores and normalize hematological parameters, thereby alleviating symptoms associated with iron deficiency, such as fatigue, pallor, and reduced cognitive function.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of iron polymaltose must be individualized based on the severity of iron deficiency, the patient's age, weight, and clinical response, as determined by serial laboratory assessments. For adults with iron deficiency anemia, a typical therapeutic dose ranges from 100 to 200 mg of elemental iron per day, usually administered in divided doses. Prophylactic doses, such as during pregnancy, may range from 30 to 60 mg of elemental iron daily. Pediatric dosing is weight-based, often around 3-5 mg of elemental iron per kilogram of body weight per day, also typically divided. Iron polymaltose is available in various oral formulations, including syrups, chewable tablets, and capsules, providing flexibility in administration. It is generally recommended to take iron polymaltose with or immediately after food to minimize gastrointestinal discomfort, although its absorption is less affected by food compared to traditional ferrous salts. Treatment duration often extends several months beyond the normalization of hemoglobin levels to ensure adequate replenishment of iron stores, typically assessed by serum ferritin levels. |
Safety & Warnings
Common Side Effects
- Iron polymaltose is generally well-tolerated, often presenting with fewer and milder gastrointestinal side effects compared to traditional ferrous iron salts due to its stable complex structure and controlled absorption.
- Common adverse reactions primarily affect the gastrointestinal system and may include nausea, constipation, diarrhea, abdominal discomfort, and a harmless black discoloration of the feces.
- Less frequently, patients may experience dyspepsia, vomiting, or flatulence.
- These symptoms are typically mild and transient, often resolving with continued use or by adjusting the dose or timing of administration.
- Allergic reactions, though rare, can occur and may manifest as skin rash, itching, or, in severe cases, anaphylaxis.
- Patients should be advised to report any persistent or severe adverse effects to their healthcare provider.
- Unlike some ferrous salts, iron polymaltose is less likely to cause metallic taste.
- Monitoring for side effects and patient education on their management are crucial components of therapy.
Serious Warnings
- Black Box Warning: Serious Warnings: Accidental Overdose Leading to Fatal Poisoning Oral iron products, including iron polymaltose, can cause serious and potentially fatal poisoning, particularly in young children. Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Even a small number of iron-containing tablets or a small amount of liquid formulation can be lethal if ingested by a child. Symptoms of iron poisoning may include abdominal pain, nausea, vomiting, diarrhea, lethargy, and shock. Severe cases can lead to metabolic acidosis, cardiovascular collapse, hepatic necrosis, and death. It is imperative that healthcare professionals counsel patients, especially parents and caregivers, on the critical importance of keeping iron polymaltose, and all other iron-containing medications, strictly out of the reach of children. In case of accidental overdose, immediate medical attention is essential. Contact a poison control center or emergency services without delay, even if the child appears well, as symptoms may be delayed or worsen rapidly. This medication is for adult use or pediatric use under strict medical guidance, and secure storage is paramount to prevent tragic outcomes.
- Several significant warnings are associated with the use of iron polymaltose.
- Foremost, accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years of age; therefore, this medication must be kept strictly out of their reach.
- Patients with conditions predisposing to iron overload, such as hemochromatosis, hemosiderosis, or certain hemolytic anemias, must avoid iron supplementation without careful medical supervision, as excessive iron accumulation can lead to severe organ damage.
- Caution is advised in individuals with inflammatory bowel disease, peptic ulcer disease, or other active gastrointestinal conditions, as iron supplementation may exacerbate symptoms.
- Concurrent use with certain medications, including antacids, proton pump inhibitors, tetracyclines, fluoroquinolones, and levothyroxine, may impair iron absorption or vice versa, necessitating dose separation.
- Chronic alcohol abuse can also impair iron absorption and increase the risk of hepatotoxicity.
- Patients should be informed that iron supplements may interfere with certain laboratory tests, such as stool occult blood tests, and may cause dark stools, which is a benign effect.
How it Works (Mechanism of Action)
Iron polymaltose is a non-ionic macromolecular complex of ferric iron (Fe3+) and polymaltose. Unlike simple iron salts (e.g., ferrous sulfate), where iron is present as free ferrous ions (Fe2+), the ferric iron in iron polymaltose is bound within a carbohydrate ligand. This stable complex structure prevents the liberation of a significant amount of free iron ions in the gastrointestinal tract, which is largely responsible for the gastric irritation and oxidative stress associated with conventional iron preparations. The absorption of iron from iron polymaltose occurs via a regulated mechanism, primarily through active uptake by enterocytes in the duodenum, where the entire complex is absorbed largely intact or after partial degradation, rather than being cleaved into free iron ions in the lumen. The iron then enters the systemic circulation, where it is delivered to the bone marrow for erythrocyte production, incorporated into myoglobin in muscle cells, and stored as ferritin in the liver and reticuloendothelial system. This controlled and targeted delivery minimizes adverse effects and maximizes therapeutic efficacy by making iron available for metabolic processes, particularly hemoglobin synthesis, which is crucial for oxygen transport throughout the body.